3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Chiyero>99.0% Lenalidomide Intermediate Factory
Ruifu Chemical ndi amene amapanga 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) yokhala ndi khalidwe lapamwamba, lapakati la Pomalidomide (CAS: 19171-19-8).Ruifu Chemical imatha kubweretsa padziko lonse lapansi, mtengo wampikisano, ntchito zabwino kwambiri, zochepa komanso zochulukirapo zomwe zilipo.Gulani 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Dzina la Chemical | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Mawu ofanana ndi mawu | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Nambala ya CAS | 24666-56-6 |
| Zogwirizana ndi CAS | 2686-86-4;25181-50-4 |
| Stock Status | Mu Stock, Kupanga Kukula Mpaka Matani |
| Molecular Formula | C5H9ClN2O2 |
| Kulemera kwa Maselo | 164.59 |
| Melting Point | 120 ℃ |
| COA & MSDS | Likupezeka |
| Chiyambi | Shanghai, China |
| Mtundu | Ruifu Chemical |
| Kanthu | Zofotokozera |
| Maonekedwe | Off-White Crystalline Powder |
| Kuyera / Kusanthula Njira | >99.0% (HPLC) |
| Chinyezi (KF) | <0.50% |
| Kutaya pa Kuyanika | <0.50% |
| Zotsalira pa Ignition | <0.20% |
| Zonse Zonyansa | <1.00% |
| Infrared Spectrum | Zimagwirizana ndi Kapangidwe |
| Test Standard | Enterprise Standard |
| Kugwiritsa ntchito | Pakati pa Lenalidomide (CAS: 191732-72-6) |
Phukusi: Botolo, Aluminiyamu zojambulazo thumba, 25kg/Cardboard Drum, kapena malinga ndi lamulo la kasitomala
Mkhalidwe Wosungira:Sungani muzitsulo zosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala ndi chinyezi
3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) ndi yapakatikati pokonzekera Lenalidomide (CAS: 191732-72-6).Lenalidomide ndi mtundu wa mankhwala oletsa kutupa omwe amapangidwa ndi makampani azachipatala aku America.Lili ndi ntchito zambiri monga anti-chotupa, chitetezo cha mthupi komanso anti-angiogenesis.Iwo akhoza ziletsa katulutsidwe wa kutupa cytokines, ndi kuonjezera katulutsidwe wa zotumphukira magazi mononuclear odana ndi yotupa cytokines.Itha kulepheretsa kukula kwa maselo angapo a myeloma ndi MM1S cell.Maphunziro awiri achipatala opangidwa ndi ma multicenter randomized double-blind blindbo-controlled placebo amayesa chitetezo ndi machiritso a lenalidomide omwe amagwiritsidwa ntchito pa multipleeloma ambiri.Zotsatira za kafukufuku waposachedwapa zachipatala zimasonyeza kuti lenalidomide sikuti imangokhala ndi zotsatira zochizira matenda a MDS ndi MM, komanso pochiza myeloma, khansa ya m'magazi, metastatic renal cell carcinoma, chotupa cholimba, idiopathic generalized amyloidosis ndi systemic bone marrow fibrosis matenda ndi m'mafupa osapsa.Mu December 2005, bungwe la US Food and Drug Administration (FDA) linavomereza kuti lenalidomide igwiritsidwe ntchito pochiza myelodysplastic syndrome (MDS).
